Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference

Rhea-AI Summary

Mirati Therapeutics (NASDAQ: MRTX) will participate in the 43rd Annual Cowen Health Care Conference on March 6, 2023, at 11:10 a.m. PT. CEO David Meek will represent the company during a fireside chat. Investors and the public can access a live webcast through the Investors and Media section on Mirati.com, with a replay available afterward.

Mirati is a biotechnology firm focused on developing targeted therapies for cancer, particularly lung cancer. Their mission is to deliver breakthrough treatments that address significant unmet needs in the oncology space.

SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate at the 43^rd Annual Cowen Health Care Conference on March 6 at 11:10 a.m. P.T. / 2:10 p.m. E.T. David Meek, chief executive officer, will represent the company in a fireside chat.

Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com. A replay of the webcast will be made available following the event.

About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. is a biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn, and Facebook.

Forward Looking Statements

This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI^™ (adagrasib), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRAS^G12D inhibitor), Mirati's technologies and Mirati' other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.

Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati' annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (www.sec.gov). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Mirati Contacts

Investor Relations: ir@mirati.com

Media Relations: media@mirati.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-to-participate-at-the-43rd-annual-cowen-health-care-conference-301752172.html

SOURCE Mirati Therapeutics, Inc.

FAQ

When will Mirati Therapeutics present at the Cowen Health Care Conference?

Mirati Therapeutics will present at the 43rd Annual Cowen Health Care Conference on March 6, 2023, at 11:10 a.m. PT.

Who will represent Mirati Therapeutics at the conference?

CEO David Meek will represent Mirati Therapeutics during the fireside chat.

How can I watch the Mirati Therapeutics conference presentation?

The presentation can be viewed live through the Investors and Media section on Mirati.com.

Will there be a replay available for the Mirati Therapeutics conference presentation?

Yes, a replay of the presentation will be available after the event.

What is the focus of Mirati Therapeutics as a biotechnology company?

Mirati Therapeutics focuses on discovering and delivering therapies for cancer, particularly targeting high unmet needs.